Cargando…
Hepatocellular carcinoma, novel therapies on the horizon
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is associated with high mortality rate. Incidence remains high due to the persistent prevalence of viral hepatitis, alcoholic cirrhosis, and non-alcoholic fatty liver disease (NFLD). Despite screening efforts, the majority of...
Autores principales: | El Dika, Imane, Makki, Iman, Abou-Alfa, Ghassan K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279038/ https://www.ncbi.nlm.nih.gov/pubmed/32527116 http://dx.doi.org/10.21037/cco-20-113 |
Ejemplares similares
-
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
por: Dika, Imane El, et al.
Publicado: (2017) -
A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2018) -
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020) -
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
por: Cervello, Melchiorre, et al.
Publicado: (2012) -
Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma
por: Chami, Perla, et al.
Publicado: (2023)